2024-09-23 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of health care products, including pharmaceuticals, medical devices, nutritionals, diagnostics, and eye care products.

**1. Performance Comparison:**

* **Cumulative Return (ABT):** 104.05%
* **Cumulative Return (VOO):** 132.53%
* **Return Difference:** -28.48%
* **Relative Divergence:** 13.9% (This means that ABT's performance is currently at the 13.9th percentile of its historical performance relative to the S&P 500).

**2. Recent Price Movements:**

* **Closing Price:** $113.7
* **5-Day Moving Average:** $115.46
* **20-Day Moving Average:** $114.71
* **60-Day Moving Average:** $109.12

The stock is currently trading below its 5-day and 20-day moving averages, indicating a potential short-term downtrend. However, the stock is above its 60-day moving average, which suggests a potential long-term upward trend.

**3. Technical Indicators:**

* **RSI:** 51.57 (Neither overbought nor oversold)
* **PPO:** -0.41 (Indicates a weak bearish momentum)
* **Delta_Previous_Relative_Divergence:** -2.1 (Short-term downtrend)
* **Expected_Return:** 70.77% (This is the potential maximum 5-year return on investment based on the current investment amount)

**4. Recent Earnings and Outlook:**

| Date       | EPS | Revenue      |
|------------|-----|--------------|
| 2024-07-31 | 0.74 | $10.38 B     |
| 2024-05-02 | 0.7  | $9.96 B      |
| 2023-11-01 | 0.82 | $10.14 B     |
| 2023-08-03 | 0.79 | $9.98 B      |
| 2024-07-31 | 0.79 | $9.98 B      |

Abbott Laboratories' most recent earnings release for the quarter ending July 31, 2024, showed an EPS of $0.74, exceeding the analysts' consensus estimate of $0.73. The company's revenue of $10.38 billion also surpassed expectations of $10.32 billion.

**5. Overall Analysis:**

* ABT has underperformed the S&P 500 in the long term but is currently showing signs of potential long-term growth based on its 60-day moving average.
* Recent price action suggests short-term weakness, with the stock trading below its 5-day and 20-day moving averages.
* Technical indicators suggest a weak bearish momentum but are not currently in overbought or oversold territory.
* Recent earnings were strong, exceeding analyst expectations.

**6. Conclusion:**

While ABT has underperformed the S&P 500 in the past, its recent strong earnings and potential long-term growth prospects make it a potentially attractive investment. However, investors should be aware of the short-term downtrend indicated by technical analysis. Further monitoring of the stock's price and technical indicators is recommended.
